EXPE vs INM · P/E 20, rev $7.74B vs rev $4.9M
Expedia Group Inc. (EXPE) versus InMed Pharmaceuticals Inc (INM) — a side-by-side from cached financials, not a winner call.
Expedia Group Inc. (EXPE) is a travel services company listed on US.
InMed Pharmaceuticals Inc (INM) is a drug manufacturers - specialty & generic company listed on US.
Latest reported EXPE revenue for 2026-06-30 was $7.74B. Net income was $872.0M. EXPE currently screens at market cap $21.71B and trailing P/E 20.4.
Latest reported INM revenue for 2025-06-30 was $4.9M. Net income was -$8.2M. INM currently screens at market cap $5.2M.
EXPE currently screens at market cap $21.71B and trailing P/E 20.4. INM currently screens at market cap $5.2M.
Not investment advice. Open the EXPE and INM stock pages for the full models.
Not investment advice.